ALERT

Due to the overwhelming surge in COVID-19 cases and the strain it has placed on health care capacity in the communities we serve, the Idaho Department of Health and Welfare has activated crisis standards of care statewide. We are open and available to see patients, but you may experience delays at our ERs, hospitals, and clinics. We appreciate your patience. Access more info on COVID testing, vaccination, visitor policy, hospitalization data, and FAQs.

toggle mobile menu Menu
toggle search menu

Site Navigation

Supplemental

Menu

Estrogen and progesterone receptor (ER/PR) tests

Estrogen and progesterone receptor (ER/PR) tests

Estrogen and progesterone receptor (ER/PR) tests identify whether these hormones affect the way that breast cancer grows. The results of these tests help doctors decide whether to use hormone therapy to help stop the cancer from growing or to lower the risk of the cancer coming back (recurrence).

The hormones estrogen and progesterone attach to certain receptors on the breast cells to stimulate the growth of normal breast cells and some breast cancers.

Breast cancer cells that lack these receptors (ER-negative and PR-negative cancers) are much less likely to respond to treatment with such medicines as tamoxifen or aromatase inhibitors. ER/PR-positive tumors have these receptors and are more likely to respond to treatment with tamoxifen or aromatase inhibitors.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Healthwise is a URAC accredited health web site content provider. Privacy Policy. How this information was developed to help you make better health decisions.

© 1995-2015 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.